Cook's New Brew in AAA Grafts
Executive Summary
Sometime in the next year or so, Cook officials hope to enter the market for peripheral vascular grafts for abdominal aortic aneurysms, a highly competitive field currently attracting companies such as Medtronic Inc., Boston Scientific Corp. and Guidant Corrp., which last year purchased AAA leader Endovascular Technologies Inc.
You may also be interested in...
Cook's New Chef Tries a Different Recipe
Top management changes at Cook are bringing subtle shifts in the company's attitude towards the marketplace. John DeFord, who has been at the company for 15 years is now president and CEO of its interventional products business, replacing Phyllis McCollough, who moves up to Chairman and EVP of operations for all of Cook Group. DeFord is spearheading Cook's new, more aggressive, opportunistic approach. A noteworthy example: Cook is embarking on a series of distribution deals with a competitor, stent market leader Guidant.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.